Burn Fat and Build Muscle From One Upstream Variable
Most research into body recomposition starts with which compound is stronger. That question skips the variable that determines what any of them can actually do.
For educational and research purposes only. This is not medical advice and is not human-use guidance. Consult a qualified professional before acting on anything here.
Start here
The variable that sits above compound choice
Before any compound decision, there is one number that determines how much fat gets mobilized and how strong the lean mass signal is. That number is GH pulse height, which is how high growth hormone climbs in the bloodstream at the peak of a release.
The reason pulse height matters more than the label on the vial is that growth hormone does not act continuously. It arrives in bursts, and the body reads the height of each burst rather than the total amount present over a day. Two research scenarios can involve similar total exposure and produce different outcomes because the shape of the release differed.
Why fat cells need a signal before anything happens
Growth hormone does not burn fat directly. What it does is signal fat cells to release stored fat into the bloodstream as free fatty acids, a process called lipolysis, which simply means the breakdown of stored fat. The fat has to be unlocked before the body can use it as fuel. Without an adequate signal, stored fat stays where it is regardless of how large a calorie deficit exists.
Think of fat cells as storage containers with a lock on each one. Growth hormone is the signal that opens those locks. The higher GH climbs at the top of a pulse, the more containers open at the same time. A weak pulse opens fewer. Based on the data, the strength of that peak is the controlling variable, not the category the compound belongs to.
The IGF-1 connection
When GH rises, the liver detects it and produces IGF-1 in proportion to the signal. IGF-1 stands for insulin-like growth factor 1, and it is the downstream hormone that drives protein synthesis, meaning the building of new muscle tissue, and tells the body to preserve the lean mass it already has. A stronger GH signal produces more IGF-1. This is why the same release that drives fat mobilization also drives the lean mass side.
This is also why the two goals are not in competition the way they are often framed. Research suggests they are downstream of the same event, which means the useful question is not how to balance fat loss against muscle retention but what determines the quality of the pulse that feeds both.
Growth hormone enters circulation and climbs toward a peak serum level. Serum simply means the liquid portion of blood that carries it.
GH binds to receptors on fat cells and sends the unlock signal. How many cells receive it at once tracks with how high the pulse climbed.
Stored fat releases into the bloodstream as free fatty acids, where it becomes available as fuel rather than remaining in storage.
The liver detects the GH signal and produces IGF-1 roughly in proportion to its strength.
IGF-1 reaches muscle tissue and signals it to build and preserve. This is the arm of the response that operates on a slower timeline than the fat side.
That chain is the whole framework. Everything else in this guide is about what raises or flattens the pulse, why the same protocol produces different results in different people, and how to think about the compound categories without collapsing them into a single ranking.
Free — no payment required
Read the rest
One email opens this guide and every other free research guide on the site. If you have already given your email anywhere on Project Theo, this will not appear again.
For educational and research purposes only. Not medical advice. No human use guidance.
Part two
What actually flattens a pulse
A pulse is not only a function of what is signaling it. It is also a function of what is suppressing it at that moment. Research consistently points to a set of inputs that lower pulse height independently of the compound involved, which is why two researchers on similar protocols can produce different reads.
Somatostatin, the brake nobody accounts for
The pituitary gland does not only receive signals telling it to release growth hormone. It also receives a braking signal called somatostatin, which tells it to slow production. That brake is engaged to some degree most of the time, and its strength varies through the day and between individuals.
This matters because it explains a common source of confusion. A signal that arrives while the brake is heavily engaged produces a lower pulse than the same signal arriving when the brake is light. Based on the data, this is one reason timing changes outcomes more than researchers usually expect, and one reason a protocol that reads well for one person reads flat for another on the same schedule.
The four suppressors
| Input | What research suggests about its effect on pulse height |
|---|---|
| Elevated insulin | Insulin rising in response to food, particularly carbohydrate, is associated with blunted GH release. This is the mechanism behind the widespread fasted-window convention, which is a timing choice rather than a rule. |
| Poor or fragmented sleep | The largest natural GH pulses occur during deep sleep. Disrupted sleep architecture reduces those pulses, which lowers the baseline the protocol is layered on top of. |
| Elevated body fat | Higher adiposity is associated with reduced GH secretion and faster clearance. This is part of why the same protocol often reads differently at different starting points. |
| Age-related decline | Natural GH output declines progressively with age. This shifts the baseline, though the size of that shift varies considerably between individuals and is not predictable from age alone. |
Interpretation note
None of these are settled outcomes for any individual. They are inputs that shift a distribution. A researcher who reads a flat result and concludes the compound failed may be reading a suppressed pulse rather than an ineffective signal, and those two situations call for different next steps.
Part three
Two categories, two different jobs
The most common framing in this space is which is stronger. That question does not resolve, because the two categories are not answering the same question. One is a support conversation and one is a replacement conversation.
What a secretagogue is doing
A GH secretagogue is a compound that signals the body to release more of its own growth hormone. Tesamorelin is a GHRH analog, meaning it mimics the natural signal the brain sends to the pituitary. The pituitary then produces the hormone itself. The clinical evidence behind tesamorelin is the strongest of any compound in this category, with research supporting meaningful visceral fat reduction, and the endogenous system, meaning the body's own production loop, stays intact.
The consequence is that the response is shaped by the body's own capacity. The signal is sent, the pituitary answers within its range, and somatostatin still applies its brake. That is a real constraint, and it is also the source of the category's main advantage: the feedback loop that limits the response is the same loop that keeps the system self-regulating.
What exogenous HGH is doing
Exogenous means from outside the body. Here the hormone itself is introduced directly into circulation rather than being requested from the pituitary. The pulse does not depend on how well the pituitary responds, how much somatostatin is present, or how the previous night's sleep went. The tradeoff is on the other side: research suggests extended exogenous use can reduce the pituitary's own output capacity over time, because a system that receives a hormone from outside consistently downregulates its own production of it.
| Question | Support category (GH secretagogues) | Replacement category (exogenous HGH) |
|---|---|---|
| What is being changed | The signal to the pituitary | The circulating level directly |
| What shapes the response | Pituitary capacity and somatostatin braking | Set by what is administered |
| Endogenous production | Preserved, the loop stays intact | Bypassed, with suppression risk over extended use |
| Variability between people | Higher, because it depends on individual pituitary response | Lower on the input side, though downstream response still varies |
| What it is solving for | Supporting a system that still functions | Replacing output the system is not producing |
| Where it belongs in a decision | A support layer question, evaluated after the foundation is stable | A clinical question that belongs with a prescriber, not a protocol spreadsheet |
Why this guide does not rank them
A dose-to-dose comparison between these categories reads as a recommendation to anyone arriving cold, and the individual variables that would determine the answer for one person are not knowable from a page. Exogenous HGH is a prescription decision. This guide covers the mechanism so the conversation with a qualified prescriber is a better one, and stops there deliberately.
Part four
Read your own pulse conditions
This is the part a PDF could not do. The items below are the pulse conditions covered above. Check the ones that currently apply. The read at the bottom updates as you go and saves to this device, so a researcher six weeks in can come back and see what changed.
This returns a read on the conditions around a pulse. It does not return a compound, a dose, or a protocol, because those depend on variables that are not visible from here.
Nothing checked yet. Work through the list above and a read will appear here.
Part five
The framework in plain terms
GH pulse height is the upstream variable. Fat mobilization requires an adequate lipolysis signal. Lean mass signaling requires adequate IGF-1 production. Both sit downstream of the same event, which is why a protocol built around one of them tends to move the other.
Once that is clear, the comparison between categories stops being about which name sounds stronger. It becomes a question about what is actually being solved. A system that still produces a reasonable pulse and needs support is a different situation from a system that is not producing one, and those two situations do not share an answer.
The four suppressors in part two are worth reading before any compound question, because a suppressed pulse and an inadequate signal look identical from the outside and call for opposite responses. Research suggests that most protocols that read flat are limited by conditions rather than by compound selection, which is a cheaper problem to fix and a more common one than it appears.
Where this guide stops
This guide covers one mechanism and the conditions around it. What it does not cover is sequencing, which is the order compounds run in and how long each phase lasts, or how a growth hormone compound interacts with everything else in a stack. Those questions depend on the full picture rather than on a single variable, and they are what the Stack Visualizer and the Protocol Builder are built to work through. Knowing what pulse height governs is the part that makes those tools worth using. It is not a substitute for them.
Takeaway
The original guide as a PDF
The page is the current version. The PDF is the takeaway if you want it offline.
Free research tool
Still have questions about your protocol?
The Project Theo Research Search Engine answers specific questions about compounds, stacking, timing, and protocol troubleshooting in seconds. Ask about pulse height, IGF-1, stall patterns, or anything else you are working through.